Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic ...

Video content above is prompted by the following: Let’s conclude by discussing our perspectives on the future of CLL treatment. How do you envision the CLL patient experience evolving in the coming ...

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

Lifestyle Expert Jennifer Bonner discusses chronic lymphocytic leukemia, or CLL, and the exciting advancements in its ...

[102] RESONATE 2 is an open-label, Phase III study of the ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL or SLL. The primary end point of this study is PFS as ...

Pembrolizumab - branded as Keytruda - will be funded from October 1, 2024, for eligible people with advanced triple-negative ...

There are roughly 2000 CLL patients in NZ, with the average age for a CLL diagnosis being between 67-72 years, so DellaBarca ...